Developmental Research Program (DRP). The goal of the University of Iowa / Mayo Clinic Lymphoma SPORE (SPORE) Developmental Research Program (DRP) is to support innovative, scientifically sound projects that investigate questions pertinent to translational lymphoma research. This program continued to be successful with support over the past 5 years going to 15 developmental research projects. Five of these projects received a second year of funding. Four of the DRP awards directly contributed to the development of the full Projects proposed in this renewal. An additional award led to an inter-SPORE trial in the renewal. In the next funding period, the DRP will provide up to $50,000 for one year ($25,000 from SPORE funds and $25,000 from institutional resources) to each of four projects each year with the possibility of a second year of support based on progress and promise. High risk/high payoff innovative concepts are encouraged. It is anticipated that support of DRP will continue to result in the generation of new hypotheses that will be tested in SPORE-sponsored research or through peer reviewed external grant support. The long- term goal of the SPORE program is to translate the findings generated by developmental projects into a reduction in the incidence and mortality rates of lymphoma.
The Specific Aims of the DRP are to 1. Encourage innovative laboratory and translationally relevant clinical studies in lymphoma 2. Foster extensive collaboration between basic science, clinical and population-based disciplines in translational research in lymphoma 3. Encourage investigators to evaluate the potential of applying their research findings to translational research in lymphoma 4. Generate new hypotheses to be tested both inside and outside the SPORE in clinical trials that may lead to significant improvements in care of patients with lymphoma

Public Health Relevance

Developmental Research Program (DRP) The SPORE Lymphoma Developmental Research Program (DRP) provides funding for innovative lymphoma research that can benefit from the unique resources provided by the SPORE. The DRP encourages proposals from investigators in related disciplines so as to rapidly translate new treatment concepts to patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097274-19
Application #
9988176
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
19
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Franqui-Machin, Reinaldo; Hao, Mu; Bai, Hua et al. (2018) Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest 128:2877-2893
Ghahramani, Grant K; Goetz, Kirsten E; Liu, Vincent (2018) Dermoscopic characterization of cutaneous lymphomas: a pilot survey. Int J Dermatol 57:339-343
Hu, G; Dasari, S; Asmann, Y W et al. (2018) Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. Leukemia 32:565-569
Moss, Jennifer L; Xiao, Qian; Matthews, Charles E (2018) Patterns of cancer-related health behaviors among middle-aged and older adults: Individual- and area-level socioeconomic disparities. Prev Med 115:31-38
Luchtel, Rebecca A; Dasari, Surendra; Oishi, Naoki et al. (2018) Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. Blood 132:1386-1398
Oishi, Naoki; Brody, Garry S; Ketterling, Rhett P et al. (2018) Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood 132:544-547
Thompson, Carrie A; Yost, Kathleen J; Maurer, Matthew J et al. (2018) Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. Hematol Oncol 36:749-756
Naik, Shruthi; Galyon, Gina D; Jenks, Nathan J et al. (2018) Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer. Mol Cancer Ther 17:316-326
Thanarajasingam, Gita; Maurer, Matthew J; Farooq, Umar et al. (2018) Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. Br J Haematol 183:149-152
Kleinstern, Geffen; Maurer, Matthew J; Liebow, Mark et al. (2018) History of autoimmune conditions and lymphoma prognosis. Blood Cancer J 8:73

Showing the most recent 10 out of 387 publications